News

Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031

BOSTON, May 16, 2017 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that the United States Patent and Trademark Office (USPTO) has allowed U.S. Patent Application No. 15/276,446, “IBAT inhibitors for the treatment of liver diseases” (‘446 patent). The ‘446 patent claims a method of treatment for Albireo’s lead product candidate A4250 in progressive familial intrahepatic cholestasis (PFIC) and other specified liver diseases. Upon issuance, the regular term of the ‘446 patent will expire in November 2031.

2017-06-27T12:04:29+00:00